Bone Mineral Density during 3 years of Growth Hormone in previously GH-treated Young Adults with PWS

in European Journal of Endocrinology
View More View Less
  • 1 L Damen, Department of Pediatrics, Subdivision of Endocrinology , Dutch Growth Research Foundation, Rotterdam, Netherlands
  • 2 L Grootjen, Department of Pediatrics, Subdivision of Endocrinology , Dutch Growth Research Foundation, Rotterdam, Netherlands
  • 3 S Donze, Department of Pediatrics, Subdivision of Endocrinology, Dutch Growth Research Foundation, Rotterdam, Netherlands
  • 4 L de Graaff, Internal medicine, division of Endocrinology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands
  • 5 J van der Velden, Pediatric endocrinology, Radboud University Medical Center / Amalia Children's Hospital, Nijmegen, Netherlands
  • 6 A Hokken-Koelega, Department of Pediatrics, Subdivision of Endocrinology, Dutch Growth Research Foundation, Rotterdam, Netherlands

Correspondence: Layla Damen, Email: l.damen@kindengroei.nl
Restricted access

Objective:

In children with Prader-Willi syndrome (PWS), growth hormone (GH) treatment has positive effects on bone mineral density (BMD). Two one-year studies did not show a difference between GH or placebo on BMD in young adults with PWS. However, there are no studies investigating BMD during longer-term GH treatment in young adults with PWS.

Design:

Open-label, prospective study in 43 young adults with PWS.

Methods:

BMD of the total body (BMDTBSDS) and lumbar spine (BMADLSSDS) measured by DXA.

Results:

In the total group, estimated mean (95% CI) BMDTB remained similar during 3 years of GH, being -0.76 (-1.11 to -0.41) SDS at start and -0.90 (-1.27 to -0.54) SDS after 3 years (p=0.11), as did BMADLS, being -0.36 (-0.72 to 0.01) SDS and -0.46 (-0.77 to -0.16) SDS resp. (p=0.16). In men, there was a significant decrease in BMDTBSDS during 3 years of GH, while BMADLSSDS remained similar. In women, both BMDTBSDS and BMADLSSDS remained similar. BMDTBSDS was associated with female sex, lean body mass and age. The majority of patients received sex steroid replacement therapy (SSRT).

Conclusions:

During 3 years of combined GH and SSRT treatment, BMD remained stable in the normal range in young adults with PWS. However, men showed a decline in BMDTBSDS, probably due to insufficient SSRT. We recommend to continue GH treatment in young adults with PWS and to start SSRT during adolescence unless puberty progresses normally.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 99 99 99
Full Text Views 9 9 9
PDF Downloads 16 16 16